$180,688.94 ownership Payment -- Merck & Co to Dr. Karen Harris
Infectious Disease Doctor Holds Significant Ownership Stake in Merck & Co.
This page provides a detailed analysis of a $180,688.94 ownership payment from Merck & Co to Dr. Karen Harris. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $180,688.94 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Merck & Co |
| Physician | Dr. Karen Harris |
| NPI Number | 1281869112 |
| Physician Specialty | Infectious Disease |
| Location | Harrisburg, PA |
| Date of Payment | 2024-05-15 |
| Related Drug/Device | Opdivo |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Merck & Co made a $180.7K ownership payment to Karen Harris, a Infectious Disease specialist in Harrisburg, PA. The payment was associated with Opdivo. Significant ownership interest reported by Dr. Karen Harris in Merck & Co. The total value of the ownership interest is $180,688.94. This ownership is related to Merck & Co.'s business, which includes drugs like Opdivo.
Patient Guidance: What This Payment Means for You
If you are a patient, understand that your doctor may have financial interests in the companies whose products they prescribe. This information is publicly available for transparency. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interests in pharmaceutical companies are less common than payments for consulting or speaking, and the value of this particular interest is substantial compared to typical direct payments for services in the Infectious Disease specialty.
Regulatory Context: Sunshine Act Requirements
Physicians are required to disclose ownership or investment interests in pharmaceutical companies as part of the CMS Open Payments program to ensure transparency in healthcare.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- pharma-investment
- merck-co
- infectious-disease
- opdivo
- physician-disclosure
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $180.7K payment for?
This was a ownership payment of $180.7K from Merck & Co to Karen Harris, categorized as "Ownership or Investment Interest". It was associated with Opdivo. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Karen Harris accept pharmaceutical money?
Yes, Karen Harris received this $180.7K payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Karen Harris's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $180.7K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Infectious Disease?
To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Karen Harris's relationship with Merck & Co?
The payment type is 'ownership', indicating a financial stake rather than a direct payment for services. This $180.7K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Infectious Disease?
The specific drug mentioned, Opdivo, is a key product for Merck & Co.
What should patients do after learning about this payment?
If you are a patient, understand that your doctor may have financial interests in the companies whose products they prescribe. This information is publicly available for transparency.
What else should I know about this ownership payment?
Dr. Harris's specialty is Infectious Disease, which may or may not directly align with Opdivo's primary indications.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.